SAN DIEGO, Sept. 9, 2021 /PRNewswire/ — Regulus Therapeutics Inc.
 (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced that Jay Hagan,…

Click here to view the original article.